linjc16/ctgov huggingface dataset:
Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio in Juvenile Idiopathic Arthritis

Study Overview
=================
Brief Summary
-----------------
The fibrinogen to albumin ratio (FAR) and C-reactive protein to albumin ratio (CAR) have emerged as useful biomarkers to predict systemic inflammation. The aim here is to investigate the relation between FAR/CAR and Juvenile arthritis disease activity score (JASDAS27) in Juvenile idiopathic arthritis (JIA)

Detailed Description
-----------------
The JADAS27 includes a selected count of the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), proximal interphalangeal joints, hips, knees and ankles.

Official Title
-----------------
Correlation of Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin Ratio With Disease Activity in Juvenile Idiopathic Arthritis

Conditions
-----------------
Juvenile Idiopathic Arthritis

Intervention / Treatment
-----------------
* Diagnostic Test: fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All juvenile idiopathic arthritis fulfilling the criteria of International League of Associations for Rheumatology (ILAR) and age and sex matched healthy subjects Exclusion Criteria: Other systemic inflammatory or autoimmune disorders. History of corticosteroid medication in the last 6 months. Liver diseases. Malignancy.

Ages Eligible for Study
-----------------
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| JIA cases<br>juvenile idiopathic arthritis cases | Diagnostic Test: fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)<br>* measurement of serum albumin, fibrinogen and CRP<br>|
| CONTROL<br>age and sex matched healthy controls | Diagnostic Test: fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)<br>* measurement of serum albumin, fibrinogen and CRP<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The fibrinogen to albumin ratio | measurement of serum fibrinogen and albumin | 3 months | 
| The CRP to albumin ratio | measurement of serum CRP and albumin | 3 MONTHS | 
| Correlation of fibrinogen to albumin and CRP to albumin ratios on one side with disease activity on the other side | correlation of these ratios with JADAS27 | 3 MONTHS |
Clinical Study of Patients Treated With PuraBond Haemostatic Agent During Abdominal Aorta Open Repair

Study Overview
=================
Brief Summary
-----------------
Purabond Study is a physician-initiated, observational, monocentric prospective Trial. The aim of the study is to investigate the hemostatic efficacy of PuraBond for aortic anastomoses and suture lines in patients with abdominal aortic pathology (aneurysmal or steno occlusive disease) candidate to open repair at Vascular Surgery Departement - San Raffaele Hospital (Milan, Italy). The Study will include 100 patients.

Official Title
-----------------
A Physician-initiated, Observational, Prospective, Monocentric Study of Patients Treated With PuraBond Haemostatic Agent During Abdominal Aorta Open Repair - PuraBond Study

Conditions
-----------------
Hemostatic

Intervention / Treatment
-----------------
* Device: Purabond


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ≥ 18 years of age, presenting with an abdominal aortic aneurysm (pararenal, juxtarenal, infrarenal, aorto-iliac mono/bilateral) Use of the Purabond hemostatic agent in patients who, in the opinion of the Physician, don't have a satisfactory surgical haemostasis Patients ≥ 18 years of age with steno-occlusive abdominal aortic or iliac disease Patients that will treated by open repair , encompassing elective, urgent and emergency presentation, hospitalized and enrolled in Vascular Surgery Unit, San Raffaele Hospital (Milan, Italy) Patients able to sign specific informed consent for the study Exclusion Criteria: Patients whom exhibited preoperative derangements in haematological and coagulation profiles, and baseline derangements in liver function Patients with abdominal aortic and/or iliac arteries disease candidate for endovascular treatment Pregnant, breastfeeding, or planning on becoming pregnant within 24 months Systemic infection (for example: sepsis) Impossibility or refusal to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with abdominal aortic pathology<br>Patients with abdominal aortic pathology (aneurysmal or steno occlusive disease) candidate to open repair with PuraBond haemostatic agent. | Device: Purabond<br>* hemostatic efficacy of PuraBond<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Hemostasis | time that goes from declamping to closing the abdomen | during the surgery |
Whole Slide Image for Predicting the Novel Grading System of Resected Lung Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the performance of a whole slide image based deep learning signature for predicting the novel grading system in resected lung adenocarcinoma based on a multicenter prospective cohort.

Official Title
-----------------
Deep Learning Signature Based on Whole Slide Images for Predicting the Novel Grading System of Resected Lung Adenocarcinoma

Conditions
-----------------
Lung Adenocarcinoma, Whole Slide Image, Novel Grading System

Intervention / Treatment
-----------------
* Diagnostic Test: Whole Slide Image based Deep Learning Signature


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathological confirmation of primary lung adenocarcinoma; Age ranging from 20-75 years; Obtained written informed consent. Exclusion Criteria: Multiple lung lesions; Poor quality of whole slide images; Participants with incomplete clinical information; Mucinous adenocarcinomas and variants; Participants who have received neoadjuvant therapy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Whole Slide Image based Deep Learning Signature|Deep Learning Signature Based on Whole Slide Image for Predicting the Novel Grading System In Resected Lung Adenocarcinoma|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the receiver operating characteristic curve | The area under the receiver operating characteristic curve of the deep learning model based on whole slide imge in predicting the novel grading system of resected lung adenocarcinoma. The novel grading system of lung adenocarcinoma includes grade I, grade II, and grade III. And the model will output the predictive values (grade I/grade II/grade III) of the grade for each patient with resected lung adenocarcinoma. | 2023.5.1-2023.10.31 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity | The sensitivity of the deep learning model based on whole slide imge in predicting the novel grading system of resected lung adenocarcinoma. The novel grading system of lung adenocarcinoma includes grade I, grade II, and grade III. And the model will output the predictive values (grade I/grade II/grade III) of the grade for each patient with resected lung adenocarcinoma. | 2023.5.1-2023.10.31 |
Validation of Numerical Simulation to Predict Proximal Deployment of Standard Stents

Study Overview
=================
Brief Summary
-----------------
Endoprosthesis treatment of aortic pathologies has become the reference in the vast majority of situations. The success of this treatment is conditioned by the choice of the endoprosthesis which must be as adapted as possible to the anatomy. This choice is currently based on manual geometric measurements performed on the preoperative scanner using conventional image processing software. The morphological result of the implantation of the endoprosthesis in the aorta is obtained by a CT scan carried out postoperatively. This scanner makes it possible to define the positioning of the endoprosthesis, the apposition surfaces between the aorta and the endoprosthesis and to predict the long-term result.

Official Title
-----------------
Validation of Numerical Simulation to Predict Proximal Deployment of Standard Stents

Conditions
-----------------
Surgery

Intervention / Treatment
-----------------
* Other: Analyzed on the post-operative scanner


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Any patient who has been treated for an aortoiliac aneurysm with a standard Medtronic Endurant aortic stent, standard Gore Excluder or conformable Gore Excluder Exclusion Criteria: Patient who has objected to the use of their data. No preoperative scanner available or insufficient injection quality Preoperative scanner with slice thickness greater than 3 mm
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient who has been treated for an aortoiliac aneurysm<br>Any patient who has been treated for an aortoiliac aneurysm with a standard Medtronic Endurant aortic stent, standard Gore Excluder or conformable Gore Excluder | Other: Analyzed on the post-operative scanner<br>* Analyzed on the post-operative scanner<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The accuracy of numerical simulation to predict the deployment at the level of the proximal neck of different types of standard stents used for the treatment of an aortoiliac aneurysm. | Wwill be evaluated by measuring the diameter and the position of the center of the first 3 simulated proximal stents will be compared to those of the real stents, analyzed on the post-operative scanner | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endoprosthesis, proximal neck, numerical simulation
Predictive Value of Preoperative Evaluation in Cases of Recurrent Endometriosis

Study Overview
=================
Brief Summary
-----------------
To investigate the effect of preoperative evaluation parameters in predicting recurrent disease in women who have undergone cystectomy or unilateral salpingo-oophorectomy due to endometriosis.

Detailed Description
-----------------
Endometriosis is an estrogen-dependent gynecological disease characterized by the presence of endometrial-like tissue outside the uterine cavity, associated with pelvic pain and subfertility. Despite its benign character, endometriosis can recur after surgery and continues to be a disease that disrupts the quality of life of millions of women. This study aimed to examine the risk factors in women who underwent cystectomy or unilateral salpingo-oophorectomy due to endometriosis but had a recurrence. Therefore, the predictive value of parameters such as preoperative biochemical parameters, cyst size and the revised American Society for Reproductive Medicine (rASRM) Scoring system will be examined in recurrent cases.

Official Title
-----------------
Predictive Value of Preoperative Evaluation in Cases of Recurrent Endometriosis

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Procedure: Surgery of endometriosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged 18-50 who had a cystectomy or unilateral oophorectomy due to endometriosis Exclusion Criteria: Women who have had bilateral oophorectomy due to endometriosis Malignant conditions Smoking Women with autoimmune disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Remission group<br>Group of women who underwent cystectomy or unilateral oophorectomy due to endometriosis but were in remission during follow-up | Procedure: Surgery of endometriosis<br>* Cystectomy or unilateral oophorectomy due to endometriosis<br>|
| Recurrent group<br>Group of women who underwent cystectomy or unilateral oophorectomy due to endometriosis but developed an endometrioma of at least 2 cm in size in a single ovary during follow-up. | Procedure: Surgery of endometriosis<br>* Cystectomy or unilateral oophorectomy due to endometriosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prediction of endometriosis recurrence | Which women are more likely to have recurrence after endometriosis surgery? | 6-180 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometriosis, prevention & control, preoperative procedures
Symptom Burden Guiding Invasive Electrophysiological Study in Paroxysmal Supraventricular Tachycardia

Study Overview
=================
Brief Summary
-----------------
BELIEVE-SVT is a European multi-centre, retrospective registry in tertiary hospitals performing electrophysiological study in patients with palpitations considered clinically suggestive of paroxysmal supraventricular tachycardia by a cardiologist and without electrocardiographic documentation of tachycardia or preexcitation. Clinical characteristics, results of electrophysiological study and ablation, complications, and clinical outcomes during follow-up will be analysed.

Detailed Description
-----------------
The Symptom Burden As Guiding Principle For Invasive Electrophysiological Study In Paroxysmal Supraventricular Tachycardia (Believe-SVT) study was a multi-centre, retrospective, observational registry carried out in tertiary European hospitals. Inclusion criteria were: symptoms that were considered suggestive of paroxysmal supraventricular tachycardia by a cardiologist and/or cardiac electrophysiologist; absence of any sort of electrocardiographic tracing during episodes (including wearables and other single lead devices), and having undergone an electrophysiological study aimed at the diagnosis of paroxysmal supraventricular tachycardia.

Official Title
-----------------
Symptom Burden Guiding Invasive Electrophysiological Study in Paroxysmal Supraventricular Tachycardia

Conditions
-----------------
Supraventricular Tachycardia

Intervention / Treatment
-----------------
* Procedure: Electrophysiological study (and ablation when appropriate)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Symptoms that were considered suggestive of paroxysmal supraventricular tachycardia by a cardiologist and/or cardiac electrophysiologist Absence of any sort of ECG tracing during episodes (including wearables and other single lead devices) Exclusion criteria: Documentation of preexcitation Prior electrophysiological study aimed at the assessment of ventriculo-atrial conduction or induction of supraventricular tachycardias.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cohort<br>Non-documented, clinically-suspected PSVT | Procedure: Electrophysiological study (and ablation when appropriate)<br>* Electrophysiological study (and ablation when appropriate)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Electrophysiological study findings | Number of participants in whom paroxysmal supraventricular tachycardia or evidence of substrate enabling paroxysmal supraventricular tachycardia is observed in electrophysiological study | 5 years |
HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADC

Study Overview
=================
Brief Summary
-----------------
To evaluate the predictive and prognostic value of HER2 expression of circulating tumor cells in HER2-positive advanced breast cancer patients treated with ADC

Official Title
-----------------
An Exploratory Clinical Study of HER2 Expression of Circulating Tumor Cells : Predictive and Prognostic Value in HER2-positive Advanced Breast Cancer Patients Treated With ADC

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Biological: HER2 expression of circulating tumor cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Has pathologically documented breast cancer that: Is unresectable or metastatic has confirmed HER2-positive expression defined as IHC 2+/ISH+ or IHC 3+ was previously treated with trastuzumab and taxane in the advanced setting or progressed within 6 months after neoadjuvant or adjuvant treatment involving a regimen including trastuzumab and taxane Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions Receives anti-HER2 ADC treatment Life expectancy > 3 months Evidence of measurable or evaluable disease (RECIST 1.1 criteria)in the 28 days before selection ECOG ≤2 Exclusion Criteria: Has uncontrolled or significant cardiovascular disease Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: HER2 expression of circulating tumor cells|Detect HER2 expression of circulating tumor cells dynamically during ADC-based treatment in HER2-positive ABC|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival(PFS) | PFS was defined as the time from the start of treatment to either the first documented disease progression or death from any cause | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate (ORR) | ORR was defined as the proportion of patients with a complete response or a partial response | 2years | 
| Overall survival(OS) | OS was defined as the time from the start of treatment to death from any cause | 5 years |
Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients

Study Overview
=================
Brief Summary
-----------------
The percentages of participants in clinical studies haven't always been perfectly representative of a particular group. This research examines the variables that affect a patient's choice to enroll in, discontinue participation in, or resume participation in a clinical trial for hairy cell leukemia. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of hairy cell leukemia studies.

Official Title
-----------------
A Look at the Patterns in Clinical Research Participation Among Patients With Hairy Cell Leukemia

Conditions
-----------------
Hairy Cell Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old Ability to understand and the willingness to sign a written informed consent document. Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. Exclusion Criteria: Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a hairy cell leukemia clinical study. |  | 3 months | 
| Number of hairy cell leukemia study participants who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hairy cell leukemia
Characterization of Myocardial Infarction Scar Using Magnetic Resonance Imaging

Study Overview
=================
Brief Summary
-----------------
The goal of this monocentric observationnal study is to describe the characteristics of the myocardial infarction scar in terms of transmurality in residual LVEF>35% patients. The primary objective is to determine the frequency of the criterion intramural scar ≥1.47cm2 (measured by MRI) in patients who presented with myocardial infarction with residual LVEF≥35%.

Official Title
-----------------
Characterization of Myocardial Infarction Scar Using Magnetic Resonance Imaging

Conditions
-----------------
Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years ; History of acute coronary syndrome prior to inclusion and having undergone cardiac MRI; LVEF >35% measured at least 6 weeks post-IDM by echocardiography or MRI; Exclusion Criteria: - Patient with an implantable cardiac device (implantable cardioverter defibrillator or pacemaker) prior to MRI.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intramural scar surface in cm² | Intramural scar surface in cm²>1.47cm² | 6 weeks after myocardial infarction | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiac magnetic resonance, sudden cardiac death, risk stratification